The world is one step closer to protecting itself against the deadly Nipah virus, thanks to the efforts of the Coalition for Epidemic Preparedness Innovations (CEPI). With a $150 million R&D portfolio, CEPI is leading the charge in developing countermeasures against this highly lethal pathogen. The focus is on creating a vaccine that can save lives, especially in regions where Nipah outbreaks have been confined to South and Southeast Asia, but the virus's natural hosts—fruit bats—range across regions that are home to more than two billion people. As human activity encroaches on bat habitats, the risk of spillover increases, making the development of a vaccine a critical priority.
The Nipah virus, discovered in 1998, has a staggering 75% mortality rate and the potential to mutate and spread globally. This has spurred scientists to develop a protective vaccine. One such vaccine, developed in a CEPI-funded partnership with the University of Oxford, became the first in the world to begin mid-stage clinical trials in Bangladesh in late 2025. Dr. K. Zaman, a leading expert in the field, oversees these trials, aiming to generate new knowledge on how a future Nipah vaccine could save lives in Bangladesh and beyond.
The vaccine's potential impact extends beyond Bangladesh, as the virus's natural hosts are found in regions with over two billion people. Rick Jarman, the Nipah programme lead at CEPI, highlights the concern over the susceptibility of domestic and farm animals to the virus, which can infect humans through contaminated food and direct contact. This susceptibility increases the risk of mutation and potential transmissibility, making the development of a vaccine a crucial step in preparedness.
CEPI's partnership with the University of Oxford and Serum Institute of India is a key part of this preparedness. This collaboration enables the manufacture of the ChAdOx1 NipahB vaccine candidate for the Phase II Bangladesh trials and aims to create an investigational-ready reserve of up to 100,000 doses. This reserve could be deployed in an outbreak, providing a rapid response to high-risk individuals.
The development of a Nipah monoclonal antibody, MBP1F5, led by ServareGMP, is another crucial aspect of CEPI's strategy. This antibody could provide immediate protection, acting as a bridge before the onset of longer-lasting vaccine-induced immunity. The combination of vaccines and mAbs offers a potent protective shield, potentially constraining an outbreak's potential.
CEPI's efforts extend beyond Nipah virus, aiming to strengthen global preparedness against the entire paramyxovirus viral family. By investing in a range of novel technologies and modalities, CEPI increases the likelihood of successful countermeasure development and validates the technology for a future Disease X. This approach supports CEPI's 100 Days Mission, which aims to accelerate vaccine timelines in response to a pandemic pathogen. Together, these preparedness measures could stop a future Nipah outbreak and reduce the threat of other viruses within the paramyxovirus family.
